Foundayo Takes Off, Telehealth Crackdown & FDA Warning! GLP-1 News

Christopher Durham and Laraine Durham break down a packed week in GLP-1 news, covering the biggest developments that could impact access, safety, and the future of treatment for patients who are using GLP-1s to treat the disease of obesity. This episode of The Downsized News dives into the early real-world performance of Foundayo, Eli Lilly’s new oral GLP-1, as prescription data begins to emerge and expectations collide with reality. They explain what those early numbers actually mean, how adoption works in the real world, and why oral options could expand access for people who have been hesitant to start injectable treatments like Zepbound, Mounjaro, Wegovy, and Ozempic. They also cover a major federal crackdown on telehealth prescribing, as the U.S. Department of Justice and Federal Trade Commission move against a company accused of illegal prescribing practices, billing issues, and misuse of patient data. Christopher and Laraine walk through what is alleged, why it matters, and how patients can protect themselves when seeking care online. On the regulatory side, the FDA has issued a warning after being denied access to parts of a compounding facility producing semaglutide and tirzepatide. The discussion focuses on what this means for patient safety, product quality, and the broader conversation around compounding and oversight. The episode also explores new clinical data from Novo Nordisk showing that oral semaglutide improved blood sugar control in adolescents with type 2 diabetes. This could expand treatment options tied to brands like Rybelsus, with future implications for Wegovy and Ozempic as the category evolves. Additional research is discussed linking GLP-1 use to reduced asthma exacerbations, along with early findings that GLP-1 may be present in joint fluid—opening the door to future research into arthritis, inflammation, and broader metabolic effects beyond weight loss. Beyond healthcare, the impact of GLP-1s is showing up across the economy. New reporting highlights how increased protein demand tied to GLP-1 use is influencing farming decisions in the United States, while international developments—including lower-cost GLP-1 options—underscore how quickly the global market is evolving. Finally, Christopher and Laraine break down new data on GLP-1 adoption and behavior changes, including how these medications are influencing eating habits, alcohol consumption, and consumer behavior. They also cover new research on stigma, showing how people using GLP-1 medications are still judged more harshly—even when they are doing the exact same work as those not using medication. As always, they bring it back to what matters most: what these changes mean for real patients navigating cost, access, and long-term treatment. +++++++++++++++++++++++++++++++++++++++ Get your Hume BodyPod today and use our exclusive Downsized code for up to 20% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. Me Again Iphone GLP-1 App: https://apps.apple.com/us/app/meagain... SHOP OUR AMAZON STORE: https://a.co/d/0gGe1MYq BOOK THE DOWNSIZED AT SEA CRUISE 2026: https://thedownsized.org/downsized-at... DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED:    / @thedownsized   FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 Foundayo Takes Off, Telehealth Crackdown & FDA Warning! 01:53 Foundayo Prescriptions Are Growing But Slower Than Expected 05:21 DOJ Moves to Shut Down Telehealth Zealthy 11:53 Ozempic Shows Results in Teens with Diabetes 15:11 FDA Warning After Inspection Denied at Compounding Facility 17:51 GLP-1s Are Changing What Farmers Grow 21:03 GLP-1 Use Is Doubling in the UK 23:48 GLP-1s Linked to Fewer Asthma Attacks in New Study 26:45 Pfizer Enters China’s GLP-1 Market at Lower Prices 29:37 GLP-1 Found in Joint Fluid What It Could Mean 32:07 Amazon Expands GLP-1 Access with One Medical 35:21 Study Shows Bias Against GLP-1 Users 41:47 Closing Thoughts